MiR-132 suppresses the invasion and metastasis of CRC cells by directly targeting ZEB2 (52) and modulates adriamycin resistance in CRC cells by targeting extracellular signal regulated kinase 1 (53). This evidence concerns the gene MAPK3 and colorectal carcinoma.